Neurocrine Biosciences (NBIX) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 03, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	NBIX
Entity Registrant Name	NEUROCRINE BIOSCIENCES INC
Entity Central Index Key	914,475
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		88,074,963

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 64,087	$ 83,267
Short-term investments, available for sale	171,493	224,083
Other current assets	3,871	3,092
Total current assets	239,451	310,442
Property and equipment, net	7,144	6,271
Long-term investments, available for sale	37,686	43,490
Restricted cash	5,083	4,883
Total assets	289,364	365,086
Current liabilities:
Accounts payable	852	5,085
Accrued liabilities	18,403	21,097
Current portion of cease-use liability	243	236
Current portion of deferred rent	513	470
Current portion of deferred gain on sale of real estate	3,552	3,526
Total current liabilities	23,563	30,414
Deferred gain on sale of real estate	6,467	7,372
Deferred revenue	10,231	10,231
Deferred rent	1,305	1,462
Cease-use liability	544	617
Other liabilities	113	113
Total liabilities	42,223	50,209
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 220,000,000 shares authorized; issued and outstanding shares were 87,519,910 as of March 31, 2017 and 86,883,300 as of December 31, 2016	88	87
Additional paid-in capital	1,381,938	1,371,432
Accumulated other comprehensive loss	(235)	(318)
Accumulated deficit	(1,134,650)	(1,056,324)
Total stockholders' equity	247,141	314,877
Total liabilities and stockholders' equity	$ 289,364	$ 365,086

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	220,000,000	220,000,000
Common stock, shares issued	87,519,910	86,883,300
Common stock, shares outstanding	87,519,910	86,883,300

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
License fees and milestones	$ 0	$ 15,000
Total revenues	0	15,000
Operating expenses:
Research and development	51,882	23,903
General and administrative	28,050	11,954
Total operating expenses	79,932	35,857
Loss from operations	(79,932)	(20,857)
Other income:
Gain on sale/disposal of assets	0	3
Deferred gain on real estate	879	853
Investment income, net	727	737
Total other income	1,606	1,593
Net loss	$ (78,326)	$ (19,264)
Net loss per common share:
Basic and diluted	$ (0.90)	$ (0.22)
Shares used in the calculation of net loss per common share:
Basic and diluted	87,283	86,497
Other comprehensive loss:
Net loss	$ (78,326)	$ (19,264)
Net unrealized gains on available-for-sale securities	83	789
Comprehensive loss	$ (78,243)	$ (18,475)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (78,326)	$ (19,264)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	489	276
Gain on sale of assets	(879)	(856)
Deferred rent	(114)	(64)
Cease-use expense	0	(584)
Amortization of premiums on investments	269	1,397
Non-cash share-based compensation expense	8,976	6,918
Change in operating assets and liabilities:
Accounts receivable under collaboration agreements and other assets	(779)	(14,577)
Accounts payable and accrued liabilities	(6,927)	(2,347)
Cease-use liability	(66)	(110)
Net cash used in operating activities	(77,357)	(29,211)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(57,877)	(55,561)
Sales and maturities of investments	116,085	126,754
Deposits and restricted cash	(200)	(200)
Proceeds from sales of property and equipment	0	3
Purchases of property and equipment	(1,362)	(741)
Net cash provided by investing activities	56,646	70,255
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	1,531	62
Net cash provided by financing activities	1,531	62
Net (decrease) increase in cash and cash equivalents	(19,180)	41,106
Cash and cash equivalents at beginning of the period	83,267	74,195
Cash and cash equivalents at end of the period	$ 64,087	$ 115,301

ORGANIZATION AND SIGNIFICANT AC

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Description of Business. ® Basis of Presentation 10-Q 10-01 S-X. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K Impact of Recently Issued Accounting Standards The Company is currently evaluating the impact of the new standard on historical revenue recorded for its two collaboration agreements. Additionally, the Company has no historical pharmaceutical product revenue but will begin to generate initial pharmaceutical product revenue in 2017. The ongoing evaluation is dependent upon the resolution of certain questions relating to the application of, and transition to, the new revenue recognition guidance for collaboration agreements. The Company’s evaluation of the new guidance is ongoing as well as the assessment of the adoption method and the ultimate impact the adoption of this standard will have on its consolidated financial statements. Based on the Company’s current assessment of the effect of the new standard on historical revenue under its collaboration agreements that is related to contingent payments, which are not dependent on performance by them, it believes revenue could potentially be recognized earlier than historically recorded if information is available to allow the Company to record the payments without the risk of a future reversal. In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02 In November 2016, the FASB issued ASU 2016-18, beginning-of-period end-of-period beginning-of-period end-of-period Use of Estimates

REVENUE RECOGNITION AND SIGNIFI

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS Revenue Recognition Policy. Since 2011, the Company has followed the Accounting Standards Codification (ASC) for Revenue Recognition – Multiple-Element Arrangements, if applicable, to determine the recognition of revenue under license and collaboration agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Company’s intellectual property, (ii) materials and technology, (iii) pharmaceutical supply, (iv) participation on joint development or joint steering committees, and (v) development services. The payments the Company receives under these arrangements typically include one or more of the following: up-front The ASC provides guidance relating to the separation of deliverables included in an arrangement into different units of accounting and the allocation of consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. The selling prices of deliverables under an arrangement may be derived using vendor specific objective evidence (VSOE), third-party evidence, or a best estimate of selling price (BESP), if VSOE or third-party evidence is not available. For most pharmaceutical licensing and collaboration agreements, BESP is utilized. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the agreement was sold on a standalone basis. Establishing BESP involves management’s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met. The Company typically receives up-front For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Company recognizes the portion of the payment allocable to delivered items as revenue when the specific milestone is achieved, and the contingency is removed. Prior to the revised multiple element guidance described above, adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Revenues from development milestones are accounted for in accordance with the Revenue Recognition – Milestone Method Topic of the FASB ASC (Milestone Method). Milestones are recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the agreement and the Company’s efforts led to the achievement of the milestone or the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance. The Company assesses whether a milestone is substantive at the inception of each agreement. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe). up-front Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company. The Company has identified the following deliverables associated with the Mitsubishi Tanabe agreement: INGREZZA technology license and existing know-how, As discussed above, the BESP method required the use of significant estimates. The Company used an income approach to estimate the selling price for the technology license and an expense approach for estimating development activities and the manufacture of pharmaceutical products. The development activities and the manufacture of pharmaceutical products are expected to be delivered throughout the duration of the agreement. The technology license and existing know-how For the year ended December 31, 2015, the Company recognized revenue under this agreement of $19.8 million associated with the delivery of a technology license and existing know-how. million up-front up-front non-contingent The Company evaluated the event-based payments under the Milestone Method and concluded only one immaterial event-based payment represents a substantive milestone. Event-based payments will be recognized when earned. The Company is eligible to receive from Mitsubishi Tanabe tiered royalty payments based on product sales in Japan and other select Asian markets. Royalties will be recognized as earned in accordance with the terms of the agreement, when product sales are reported by Mitsubishi Tanabe, the amount can be reasonably estimated, and collectability is reasonably assured. AbbVie Inc. ( AbbVie ) Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. During the first quarter of 2016, event-based revenue of $15.0 million was recognized related to AbbVie’s initiation of Phase III development of elagolix in uterine fibroids. No revenue has been recognized during 2017 under this collaboration agreement.

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2017
Investments Schedule [Abstract]
INVESTMENTS	3. INVESTMENTS Available-for-sale available-for-sale available-for-sale Investments consist of the following ( in thousands March 31, 2017 December 31, 2016 Certificates of deposit $ 240 $ 960 Commercial paper 44,392 49,245 Corporate debt securities 136,587 204,436 Securities of government sponsored entities 27,960 12,932 Total investments $ 209,179 $ 267,573 The following is a summary of investments classified as available-for-sale in thousands Contractual Maturity (in years) Amortized Cost Gross Unrealized Gains(1) Gross Unrealized Losses(1) Aggregate Estimated Fair Value March 31, 2017: Classified as current assets: Certificates of deposit Less than 1 $ 240 $ — $ — $ 240 Commercial paper Less than 1 44,406 2 (16 ) 44,392 Corporate debt securities Less than 1 118,969 7 (112 ) 118,864 Securities of government-sponsored entities Less than 1 8,003 — (6 ) 7,997 Total short-term available-for-sale $ 171,618 $ 9 $ (134 ) $ 171,493 Classified as non-current Corporate debt securities 1 to 2 $ 17,793 $ — $ (70 ) $ 17,723 Securities of government-sponsored entities 1 to 2 20,003 — (40 ) 19,963 Total long-term available-for-sale $ 37,796 $ — $ (110 ) $ 37,686 December 31, 2016: Classified as current assets: Certificates of deposit Less than 1 $ 960 $ — $ — $ 960 Commercial paper Less than 1 49,280 3 (38 ) 49,245 Corporate debt securities Less than 1 168,548 3 (117 ) 168,434 Securities of government-sponsored entities Less than 1 5,448 — (4 ) 5,444 Total short-term available-for-sale $ 224,236 $ 6 $ (159 ) $ 224,083 Classified as non-current Corporate debt securities 1 to 2 $ 36,149 $ — $ (147 ) $ 36,002 Securities of government-sponsored entities 1 to 2 7,506 — (18 ) 7,488 Total long-term available-for-sale $ 43,655 $ — $ (165 ) $ 43,490 (1) Unrealized gains and losses are included in other comprehensive loss. The following table presents gross unrealized losses and fair value for those available-for-sale in thousands Less Than 12 Months 12 Months or Greater Total Estimated Fair Value Unrealized Losses Estimated Fair Value Unrealized Losses Estimated Fair Value Unrealized Losses March 31, 2017: Commercial paper $ 38,914 $ (16 ) $ — $ — $ 38,914 $ (16 ) Corporate debt securities 120,973 (182 ) — — 120,973 (182 ) Securities of government-sponsored entities 27,960 (46 ) — — 27,960 (46 ) Total $ 187,847 $ (244 ) $ — $ — $ 187,847 $ (244 ) December 31, 2016: Commercial paper $ 43,781 $ (38 ) $ — $ — $ 43,781 $ (38 ) Corporate debt securities 185,243 (261 ) 9,144 (3 ) 194,387 (264 ) Securities of government-sponsored entities 12,932 (22 ) — — 12,932 (22 ) Total $ 241,956 $ (321 ) $ 9,144 $ (3 ) $ 251,100 $ (324 ) The primary objective of the Company’s investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. The Company’s investment policy limits interest-bearing security investments to certain types of instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer. The Company reviews the available-for-sale available-for-sale

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided The Company’s assets which were measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 were determined using the inputs described above and are as follows ( in millions Fair Value Measurements Using Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2017: Classified as current assets: Cash and money market funds $ 60.5 $ 60.5 $ — $ — Certificates of deposit 0.2 0.2 — — Commercial paper 44.4 — 44.4 — Securities of government-sponsored entities 8.0 — 8.0 — Corporate debt securities 122.5 — 122.5 — Subtotal 235.6 60.7 174.9 — Classified as long-term assets: Certificates of deposit 5.1 5.1 — — Securities of government-sponsored entities 20.0 — 20.0 — Corporate debt securities 17.7 — 17.7 — Total 278.4 65.8 212.6 — Less cash, cash equivalents and restricted cash (69.2 ) (65.5 ) (3.7 ) — Total investments $ 209.2 $ 0.3 $ 208.9 $ — December 31, 2016: Classified as current assets: Cash and money market funds $ 73.6 $ 73.6 $ — $ — Certificates of deposit 1.0 1.0 — — Commercial paper 49.2 — 49.2 — Securities of government-sponsored entities 5.4 — 5.4 — Corporate debt securities 178.1 — 178.1 — Subtotal 307.3 74.6 232.7 — Classified as long-term assets: Certificates of deposit 4.9 4.9 — — Securities of government-sponsored entities 7.5 — 7.5 — Corporate debt securities 36.0 — 36.0 — Total 355.7 79.5 276.2 — Less cash, cash equivalents and restricted cash (88.1 ) (78.5 ) (9.6 ) — Total investments $ 267.6 $ 1.0 $ 266.6 $ —

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	5. SHARE-BASED COMPENSATION The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows ( in millions Three Months Ended March 31, 2017 2016 General and administrative $ 5.5 $ 4.1 Research and development 3.5 2.8 Total share-based compensation expense $ 9.0 $ 6.9 The fair value of equity instruments that vest based on continued employee service is recognized and amortized on a straight-line basis over the requisite service period. For restricted stock units (RSUs) with performance-based vesting requirements (PRSUs), no expense is recorded until the performance condition is probable of being achieved. As of March 31, 2017, total unrecognized estimated compensation cost related to non-vested non-vested During the three months ended March 31, 2017 and 2016, stock options to purchase approximately 0.3 million and 26,000 shares of the Company’s common stock were exercised, respectively. The cash received by the Company from stock option exercises during the three months ended March 31, 2017 and 2016 was approximately $1.5 million and $0.1 million, respectively. The Company also issued approximately 0.3 million shares of common stock pursuant to the vesting of RSUs during each of the three months ended March 31, 2017 and 2016. Stock Option Assumptions The Company granted stock options to purchase approximately 1.4 million and 0.7 million shares of the Company’s common stock during the three months ended March 31, 2017 and 2016, respectively. These stock options generally vest monthly over a four-year period. The exercise price of all stock options granted during the three months ended March 31, 2017 and 2016 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants: Three Months Ended March 31, 2017 2016 Risk-free interest rate 2.0 % 1.4 % Expected volatility of common stock 58.1 % 60.0 % Dividend yield 0.0 % 0.0 % Expected option term 5.8 years 5.6 years The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. For the three months ended March 31, 2017 and 2016, share-based compensation expense related to stock options was $5.7 million and $4.4 million, respectively. Restricted Stock Units During the three months ended March 31, 2017 and 2016, the Company granted approximately 0.4 million and 0.3 million RSUs, respectively, that vest annually over a four year period. Additionally, during the three months ended March 31, 2016, the Company granted approximately 0.2 million PRSUs. These PRSUs vest based on the achievement of pre-defined

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
STOCKHOLDERS' EQUITY	6. STOCKHOLDERS’ EQUITY Shelf Registration Statements In February 2017, the Company filed an automatic shelf registration statement which immediately became effective by rule of the SEC. For so long as the Company continues to satisfy the requirements to be deemed a well-known seasoned issuer, this shelf registration statement allows the Company to issue an unlimited number of securities from time to time. As of March 31, 2017, the Company had not sold any securities under this shelf registration statement. The specific terms of future offerings, if any, under any of the shelf registration statements would be established at the time of such offerings.

REAL ESTATE

REAL ESTATE	3 Months Ended
	Mar. 31, 2017
Leases [Abstract]
REAL ESTATE	7. REAL ESTATE In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement. Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building. The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance. The Company recognized $0.9 million of the deferred gain during each of the three month periods ending March 31, 2017 and 2016, and will recognize the remaining $10.0 million of the deferred gain over the initial Lease term which will expire at the end of 2019. Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. issued on the Company’s behalf a letter of credit in the amount of $4.6 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year As of March 31, 2017, the Company had one sublease agreement for approximately 16,000 square feet of the Rear Building. This sublease is expected to result in approximately $0.6 million of rental income in 2017 with this sublease rental income being recorded as an offset to rent expense. The income generated under this sublease is lower than the Company’s financial obligation under the Lease for the Rear Building, as determined on a per square foot basis. Consequently, at the inception of such a sublease, or in association with an amendment to such sublease, the Company is required to record a cease-use one-year The following table sets forth changes to the accrued cease-use in thousands Three Months Ended March 31, 2017 2016 Beginning balance $ 853 $ 1,983 Change in estimate (1) — (830 ) Payments (66 ) (110 ) Ending balance $ 787 $ 1,043 (1) Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
LOSS PER COMMON SHARE	8. LOSS PER COMMON SHARE The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. In computing the diluted net loss, potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options and warrants and the vesting of RSUs and PRSUs, are excluded from the diluted loss per share calculation because of their anti-dilutive effect. For the three months ended March 31, 2017 and March 31, 2016, the Company realized a net loss of $78.3 million and $19.3 million, respectively. Options to purchase approximately 1.4 million and 0.5 million shares of common stock were outstanding during the three months ended March 31, 2017 and 2016, respectively, with an exercise price greater than the average market price of the underlying common shares.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	3 Months Ended
	Mar. 31, 2017
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT	9. RESEARCH AND DEVELOPMENT R&D expenses consist primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing

BIAL AGREEMENT

BIAL AGREEMENT	3 Months Ended
	Mar. 31, 2017
Text Block [Abstract]
BIAL AGREEMENT	10. BIAL AGREEMENT On February 9, 2017, the Company entered into an exclusive license agreement with BIAL– Portela & CA, S.A. (BIAL) for the development and commercialization of opicapone for the treatment of human diseases and conditions, including Parkinson’s disease, in the United States and Canada. Under the terms of the agreement, the Company is responsible for the management and cost of all opicapone development and commercialization activities in the United States and Canada. Under the terms of the agreement, the Company paid BIAL an upfront license fee of $30 million, and may also be required to pay up to an additional $115 million in milestone payments associated with the regulatory approval and net sales of products containing opicapone. The initial upfront license fee was expensed in the first quarter of 2017 as in-process The agreement, unless terminated earlier, will continue on a licensed product by licensed product and country by country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country. Upon the Company’s written request prior to the estimated expiration of the term in respect of a licensed product, the parties shall negotiate a good faith continuation of BIAL’s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, the Company shall pay BIAL a trademark royalty based on the net sales of such licensed product. Either party may terminate the agreement earlier if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party’s insolvency. BIAL may terminate the agreement if the Company fails to use commercially reasonable efforts or fails to file an NDA for a licensed product by a specified date or under certain circumstances involving a change of control of the Company. In certain circumstances where BIAL elects to terminate the agreement in connection with the Company’s change of control, BIAL shall pay the Company a termination fee. The Company may terminate the agreement at any time for any reason upon six months written notice to BIAL if prior to the first NDA approval in the United States, and upon nine months written notice to BIAL if such notice is given after the first NDA approval in the United States. If the Company’s termination request occurs prior to the first NDA approval in the United States, the Company will have to pay BIAL a termination fee except under certain conditions specified in the agreement.

COMMITMENTS & CONTINGENCIES

COMMITMENTS & CONTINGENCIES	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS & CONTINGENCIES	11. COMMITMENTS & CONTINGENCIES On December 1, 2015, Icahn School of Medicine at Mount Sinai (Mount Sinai) filed a complaint against the Company in the United States District Court for the Southern District of New York: Icahn School of Medicine at Mount Sinai v. Neurocrine Biosciences, Inc., Case No. 1:15-cv-09414. In the complaint, Mount Sinai alleges that the Company, by entering into an exclusive worldwide collaboration with AbbVie to develop and commercialize next-generation GnRH antagonists, breached a license agreement with Mount Sinai dated August 27, 1999 (Mount Sinai License). Mount Sinai is seeking unspecified monetary damages, future sublicensing fees and attorney’s fees. In January 2016, the Company filed a motion to dismiss this complaint in its entirety. In June 2016, the Court denied the motion in part and granted the motion in part, ruling that while Mount Sinai could continue its lawsuit against the Company, there was no requirement by the Company to obtain Mount Sinai’s consent prior to licensing the next-generation GnRH antagonists to AbbVie. In July 2016, the Company filed its answer denying Mount Sinai’s allegations, and filed counterclaims against Mount Sinai alleging patent misuse, non-infringement of Mount Sinai’s patents, and that Mount Sinai’s patents that are subject to the Mount Sinai License are invalid. Mount Sinai filed a motion to dismiss the Company’s counterclaims and affirmative defenses, which the court granted. The Company believes that it has meritorious defenses to the claims made in the complaint and intends to vigorously defend against such claims, but is not able to predict the ultimate outcome of this action, or estimate any potential loss. The Company is not aware of any other proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENT	12. SUBSEQUENT EVENT In May 2017, the Company issued $517.5 million aggregate principal amount of 2.25% Convertible Senior Notes due May 2024. Debt issuance costs of approximately $15.3 million were primarily comprised of initial purchasers’ discounts and commissions, legal, accounting, and other professional fees, a portion of which will be capitalized and are recorded as a reduction to long-term debt and are being amortized using the effective interest method to interest expense over the seven-year term of the notes. The remaining debt issuance costs will be allocated as a component of equity in additional paid-in The notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock based on an initial conversion rate, subject to adjustment, of 13.1711 shares per $1,000 principal amount of the notes (which represents an initial conversion price of approximately $75.92 per share). The notes will mature on May 15, 2024, unless earlier converted, redeemed or repurchased. Prior to the close of business on the business day immediately preceding January 15, 2024, the notes will be convertible at the option of the holders only upon satisfaction of certain circumstances. Thereafter, the notes will be convertible at the option of the holders at any time up until the close of business on the scheduled trading day immediately preceding May 15, 2024. The Company may not redeem the notes prior to May 15, 2021. On or after this date, the Company, at its election, may redeem all, or any portion, of the notes for cash if the last reported sales price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day immediately preceding the date which the Company sends the related redemption notice, is more than 130% of the conversion price of the notes in effect on each applicable trading day. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day The Company pays 2.25% interest per annum on the principal amount of the notes semi-annually in arrears in cash on May 15 and November 15 of each year. The Company will account separately for the liability and equity components of the notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. If a fundamental change, as defined in the indenture for the notes, such as an acquisition, merger, or liquidation of the Company, occurs prior to the maturity date, subject to certain limitations, holders of the notes may require the Company to repurchase all or a portion of their notes for cash at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest, and additional fees.

ORGANIZATION AND SIGNIFICANT 18

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Description of Business	Description of Business. ®
Basis of Presentation	Basis of Presentation 10-Q 10-01 S-X. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards The Company is currently evaluating the impact of the new standard on historical revenue recorded for its two collaboration agreements. Additionally, the Company has no historical pharmaceutical product revenue but will begin to generate initial pharmaceutical product revenue in 2017. The ongoing evaluation is dependent upon the resolution of certain questions relating to the application of, and transition to, the new revenue recognition guidance for collaboration agreements. The Company’s evaluation of the new guidance is ongoing as well as the assessment of the adoption method and the ultimate impact the adoption of this standard will have on its consolidated financial statements. Based on the Company’s current assessment of the effect of the new standard on historical revenue under its collaboration agreements that is related to contingent payments, which are not dependent on performance by them, it believes revenue could potentially be recognized earlier than historically recorded if information is available to allow the Company to record the payments without the risk of a future reversal. In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02 In November 2016, the FASB issued ASU 2016-18, beginning-of-period end-of-period beginning-of-period end-of-period
Use of Estimates	Use of Estimates
Revenue Recognition Policy	Revenue Recognition Policy. Since 2011, the Company has followed the Accounting Standards Codification (ASC) for Revenue Recognition – Multiple-Element Arrangements, if applicable, to determine the recognition of revenue under license and collaboration agreements. The terms of these agreements generally contain multiple elements, or deliverables, which may include (i) licenses to the Company’s intellectual property, (ii) materials and technology, (iii) pharmaceutical supply, (iv) participation on joint development or joint steering committees, and (v) development services. The payments the Company receives under these arrangements typically include one or more of the following: up-front The ASC provides guidance relating to the separation of deliverables included in an arrangement into different units of accounting and the allocation of consideration to the units of accounting. The evaluation of multiple-element arrangements requires management to make judgments about (i) the identification of deliverables, (ii) whether such deliverables are separable from the other aspects of the contractual relationship, (iii) the estimated selling price of each deliverable, and (iv) the expected period of performance for each deliverable. To determine the units of accounting under a multiple-element arrangement, management evaluates certain separation criteria, including whether the deliverables have stand-alone value, based on the relevant facts and circumstances for each arrangement. The selling prices of deliverables under an arrangement may be derived using vendor specific objective evidence (VSOE), third-party evidence, or a best estimate of selling price (BESP), if VSOE or third-party evidence is not available. For most pharmaceutical licensing and collaboration agreements, BESP is utilized. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the agreement was sold on a standalone basis. Establishing BESP involves management’s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. The allocated consideration for each unit of accounting is recognized over the related obligation period in accordance with the applicable revenue recognition criteria. If there are deliverables in an arrangement that are not separable from other aspects of the contractual relationship, they are treated as a combined unit of accounting, with the allocated revenue for the combined unit recognized in a manner consistent with the revenue recognition applicable to the final deliverable in the combined unit. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as unearned revenue in the accompanying balance sheets and recognized as revenue when the related revenue recognition criteria are met. The Company typically receives up-front For payments payable on achievement of milestones that do not meet all of the conditions to be considered substantive, the Company recognizes the portion of the payment allocable to delivered items as revenue when the specific milestone is achieved, and the contingency is removed. Prior to the revised multiple element guidance described above, adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Revenues from development milestones are accounted for in accordance with the Revenue Recognition – Milestone Method Topic of the FASB ASC (Milestone Method). Milestones are recognized when earned, as evidenced by written acknowledgment from the collaborator or other persuasive evidence that the milestone has been achieved, provided that the milestone event is substantive. A milestone event is considered to be substantive if its achievability was not reasonably assured at the inception of the agreement and the Company’s efforts led to the achievement of the milestone or the milestone was due upon the occurrence of a specific outcome resulting from the Company’s performance. The Company assesses whether a milestone is substantive at the inception of each agreement. Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe). up-front Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company. The Company has identified the following deliverables associated with the Mitsubishi Tanabe agreement: INGREZZA technology license and existing know-how, As discussed above, the BESP method required the use of significant estimates. The Company used an income approach to estimate the selling price for the technology license and an expense approach for estimating development activities and the manufacture of pharmaceutical products. The development activities and the manufacture of pharmaceutical products are expected to be delivered throughout the duration of the agreement. The technology license and existing know-how For the year ended December 31, 2015, the Company recognized revenue under this agreement of $19.8 million associated with the delivery of a technology license and existing know-how. million up-front up-front non-contingent The Company evaluated the event-based payments under the Milestone Method and concluded only one immaterial event-based payment represents a substantive milestone. Event-based payments will be recognized when earned. The Company is eligible to receive from Mitsubishi Tanabe tiered royalty payments based on product sales in Japan and other select Asian markets. Royalties will be recognized as earned in accordance with the terms of the agreement, when product sales are reported by Mitsubishi Tanabe, the amount can be reasonably estimated, and collectability is reasonably assured. AbbVie Inc. ( AbbVie ) Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company. During the first quarter of 2016, event-based revenue of $15.0 million was recognized related to AbbVie’s initiation of Phase III development of elagolix in uterine fibroids. No revenue has been recognized during 2017 under this collaboration agreement.

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2017
Investments Schedule [Abstract]
Investments	Investments consist of the following ( in thousands March 31, 2017 December 31, 2016 Certificates of deposit $ 240 $ 960 Commercial paper 44,392 49,245 Corporate debt securities 136,587 204,436 Securities of government sponsored entities 27,960 12,932 Total investments $ 209,179 $ 267,573
Summary of Investments Classified as Available-For-Sale Securities	The following is a summary of investments classified as available-for-sale in thousands Contractual Maturity (in years) Amortized Cost Gross Unrealized Gains(1) Gross Unrealized Losses(1) Aggregate Estimated Fair Value March 31, 2017: Classified as current assets: Certificates of deposit Less than 1 $ 240 $ — $ — $ 240 Commercial paper Less than 1 44,406 2 (16 ) 44,392 Corporate debt securities Less than 1 118,969 7 (112 ) 118,864 Securities of government-sponsored entities Less than 1 8,003 — (6 ) 7,997 Total short-term available-for-sale $ 171,618 $ 9 $ (134 ) $ 171,493 Classified as non-current Corporate debt securities 1 to 2 $ 17,793 $ — $ (70 ) $ 17,723 Securities of government-sponsored entities 1 to 2 20,003 — (40 ) 19,963 Total long-term available-for-sale $ 37,796 $ — $ (110 ) $ 37,686 December 31, 2016: Classified as current assets: Certificates of deposit Less than 1 $ 960 $ — $ — $ 960 Commercial paper Less than 1 49,280 3 (38 ) 49,245 Corporate debt securities Less than 1 168,548 3 (117 ) 168,434 Securities of government-sponsored entities Less than 1 5,448 — (4 ) 5,444 Total short-term available-for-sale $ 224,236 $ 6 $ (159 ) $ 224,083 Classified as non-current Corporate debt securities 1 to 2 $ 36,149 $ — $ (147 ) $ 36,002 Securities of government-sponsored entities 1 to 2 7,506 — (18 ) 7,488 Total long-term available-for-sale $ 43,655 $ — $ (165 ) $ 43,490 (1) Unrealized gains and losses are included in other comprehensive loss.
Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position	The following table presents gross unrealized losses and fair value for those available-for-sale in thousands Less Than 12 Months 12 Months or Greater Total Estimated Fair Value Unrealized Losses Estimated Fair Value Unrealized Losses Estimated Fair Value Unrealized Losses March 31, 2017: Commercial paper $ 38,914 $ (16 ) $ — $ — $ 38,914 $ (16 ) Corporate debt securities 120,973 (182 ) — — 120,973 (182 ) Securities of government-sponsored entities 27,960 (46 ) — — 27,960 (46 ) Total $ 187,847 $ (244 ) $ — $ — $ 187,847 $ (244 ) December 31, 2016: Commercial paper $ 43,781 $ (38 ) $ — $ — $ 43,781 $ (38 ) Corporate debt securities 185,243 (261 ) 9,144 (3 ) 194,387 (264 ) Securities of government-sponsored entities 12,932 (22 ) — — 12,932 (22 ) Total $ 241,956 $ (321 ) $ 9,144 $ (3 ) $ 251,100 $ (324 )

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The Company’s assets which were measured at fair value on a recurring basis as of March 31, 2017 and December 31, 2016 were determined using the inputs described above and are as follows ( in millions Fair Value Measurements Using Carrying Value Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) March 31, 2017: Classified as current assets: Cash and money market funds $ 60.5 $ 60.5 $ — $ — Certificates of deposit 0.2 0.2 — — Commercial paper 44.4 — 44.4 — Securities of government-sponsored entities 8.0 — 8.0 — Corporate debt securities 122.5 — 122.5 — Subtotal 235.6 60.7 174.9 — Classified as long-term assets: Certificates of deposit 5.1 5.1 — — Securities of government-sponsored entities 20.0 — 20.0 — Corporate debt securities 17.7 — 17.7 — Total 278.4 65.8 212.6 — Less cash, cash equivalents and restricted cash (69.2 ) (65.5 ) (3.7 ) — Total investments $ 209.2 $ 0.3 $ 208.9 $ — December 31, 2016: Classified as current assets: Cash and money market funds $ 73.6 $ 73.6 $ — $ — Certificates of deposit 1.0 1.0 — — Commercial paper 49.2 — 49.2 — Securities of government-sponsored entities 5.4 — 5.4 — Corporate debt securities 178.1 — 178.1 — Subtotal 307.3 74.6 232.7 — Classified as long-term assets: Certificates of deposit 4.9 4.9 — — Securities of government-sponsored entities 7.5 — 7.5 — Corporate debt securities 36.0 — 36.0 — Total 355.7 79.5 276.2 — Less cash, cash equivalents and restricted cash (88.1 ) (78.5 ) (9.6 ) — Total investments $ 267.6 $ 1.0 $ 266.6 $ —

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Expenses Related to Share Based Compensation	The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows ( in millions Three Months Ended March 31, 2017 2016 General and administrative $ 5.5 $ 4.1 Research and development 3.5 2.8 Total share-based compensation expense $ 9.0 $ 6.9
Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model	The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants: Three Months Ended March 31, 2017 2016 Risk-free interest rate 2.0 % 1.4 % Expected volatility of common stock 58.1 % 60.0 % Dividend yield 0.0 % 0.0 % Expected option term 5.8 years 5.6 years

REAL ESTATE (Tables)

REAL ESTATE (Tables)	3 Months Ended
	Mar. 31, 2017
Leases [Abstract]
Changes to Accrued Cease-Use Liability	The following table sets forth changes to the accrued cease-use in thousands Three Months Ended March 31, 2017 2016 Beginning balance $ 853 $ 1,983 Change in estimate (1) — (830 ) Payments (66 ) (110 ) Ending balance $ 787 $ 1,043 (1) Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

Revenue Recognition and Signi23

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2010	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015
Mitsubishi Tanabe
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received				$ 30,000,000
Collaborative agreement maximum additional payment to receive				85,000,000
Patent rights period		The longer of ten years or the life of the related patent rights.
Clinical trial cost				12,000,000
Collaborative arrangement right description		Under the terms of the Company’s agreement with Mitsubishi Tanabe, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by a joint steering committee and joint development committee with representatives from both the Company and Mitsubishi Tanabe. There are no performance, cancellation, termination or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days’ written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company.
Collaboration termination notice period		180 days
Revenues recognized under collaboration agreement		$ 0	$ 0	19,800,000
Deferred revenues under collaboration				$ 10,200,000
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$ 75,000,000
Patent rights period		Ten years or the life of the related patent rights.
Collaborative arrangement right description		The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Collaboration termination notice period		180 days
Revenues recognized under collaboration agreement		$ 0	$ 15,000,000
Amount remains outstanding under collaboration agreement		485,000,000
AbbVie | Development and Regulatory Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive		480,000,000
Collaborative agreement payment received		45,000,000
AbbVie | Commercial Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive		$ 50,000,000

Investments (Detail)

Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Investments [Line Items]
Investments	$ 209,179	$ 267,573
Certificates of deposit
Schedule of Investments [Line Items]
Investments	240	960
Commercial paper
Schedule of Investments [Line Items]
Investments	44,392	49,245
Corporate debt securities
Schedule of Investments [Line Items]
Investments	136,587	204,436
Domestic and foreign government agencies debt securities
Schedule of Investments [Line Items]
Investments	$ 27,960	$ 12,932

Summary of Investments Classifi

Summary of Investments Classified as Available-For-Sale Securities (Detail) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		$ 209,179	$ 267,573
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		240	960
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		44,392	49,245
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		136,587	204,436
Domestic and foreign government agencies debt securities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value		27,960	12,932
Short-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		171,618	224,236
Gross Unrealized Gains	[1]	9	6
Gross Unrealized Losses	[1]	(134)	(159)
Aggregate Estimated Fair Value		171,493	224,083
Short-term investments | Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		240	960
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	0	0
Aggregate Estimated Fair Value		$ 240	$ 960
Short-term investments | Certificates of deposit | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 44,406	$ 49,280
Gross Unrealized Gains	[1]	2	3
Gross Unrealized Losses	[1]	(16)	(38)
Aggregate Estimated Fair Value		$ 44,392	$ 49,245
Short-term investments | Commercial paper | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 118,969	$ 168,548
Gross Unrealized Gains	[1]	7	3
Gross Unrealized Losses	[1]	(112)	(117)
Aggregate Estimated Fair Value		$ 118,864	$ 168,434
Short-term investments | Corporate debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Short-term investments | Domestic and foreign government agencies debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 8,003	$ 5,448
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	(6)	(4)
Aggregate Estimated Fair Value		$ 7,997	$ 5,444
Short-term investments | Domestic and foreign government agencies debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 37,796	$ 43,655
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	(110)	(165)
Aggregate Estimated Fair Value		37,686	43,490
Long-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		17,793	36,149
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	(70)	(147)
Aggregate Estimated Fair Value		$ 17,723	$ 36,002
Long-term investments | Corporate debt securities | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments | Corporate debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		2 years	2 years
Long-term investments | Domestic and foreign government agencies debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 20,003	$ 7,506
Gross Unrealized Gains	[1]	0	0
Gross Unrealized Losses	[1]	(40)	(18)
Aggregate Estimated Fair Value		$ 19,963	$ 7,488
Long-term investments | Domestic and foreign government agencies debt securities | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		1 year	1 year
Long-term investments | Domestic and foreign government agencies debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity		2 years	2 years
[1]	(1) Unrealized gains and losses are included in other comprehensive loss.

Gross Unrealized Losses and Fai

Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	$ 187,847	$ 241,956
Less Than 12 Months, Unrealized Losses	(244)	(321)
12 Months or Greater, Estimated Fair Value	0	9,144
12 Months or Greater, Unrealized Losses	0	(3)
Total Estimated Fair Value	187,847	251,100
Total Unrealized Losses	(244)	(324)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	38,914	43,781
Less Than 12 Months, Unrealized Losses	(16)	(38)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	38,914	43,781
Total Unrealized Losses	(16)	(38)
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	120,973	185,243
Less Than 12 Months, Unrealized Losses	(182)	(261)
12 Months or Greater, Estimated Fair Value	0	9,144
12 Months or Greater, Unrealized Losses	0	(3)
Total Estimated Fair Value	120,973	194,387
Total Unrealized Losses	(182)	(264)
Domestic and foreign government agencies debt securities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	27,960	12,932
Less Than 12 Months, Unrealized Losses	(46)	(22)
12 Months or Greater, Estimated Fair Value	0	0
12 Months or Greater, Unrealized Losses	0	0
Total Estimated Fair Value	27,960	12,932
Total Unrealized Losses	$ (46)	$ (22)

Assets Measured at Fair Value o

Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	$ 209.2	$ 267.6
Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	235.6	307.3
Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	60.5	73.6
Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0.2	1
Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	44.4	49.2
Short-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	8	5.4
Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	122.5	178.1
Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	5.1	4.9
Long-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	20	7.5
Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	17.7	36
Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	278.4	355.7
Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	69.2	88.1
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.3	1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	60.7	74.6
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	60.5	73.6
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.2	1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	5.1	4.9
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	65.8	79.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	65.5	78.5
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	208.9	266.6
Significant Other Observable Inputs (Level 2) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	174.9	232.7
Significant Other Observable Inputs (Level 2) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	44.4	49.2
Significant Other Observable Inputs (Level 2) | Short-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	8	5.4
Significant Other Observable Inputs (Level 2) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	122.5	178.1
Significant Other Observable Inputs (Level 2) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Other Observable Inputs (Level 2) | Long-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	20	7.5
Significant Other Observable Inputs (Level 2) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	17.7	36
Significant Other Observable Inputs (Level 2) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	212.6	276.2
Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	3.7	9.6
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Cash and money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Short-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Domestic and foreign government agencies debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Long-term investments | Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Investments Including Cash Equivalents And Restricted Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0	0
Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	$ 0	$ 0

Compensation Expense Related to

Compensation Expense Related to Share-Based Compensation (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 9	$ 6.9
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	5.5	4.1
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 3.5	$ 2.8

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option exercised	300,000	26,000
Cash received from stock option exercises	$ 1.5	$ 0.1
Common stock issued pursuant to the vesting of restricted stock units (RSUs)	300,000	300,000
Stock options granted	1,400,000	700,000
Share-based compensation expense	$ 9	$ 6.9
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 57.5
Stock vesting period	3 years 1 month 6 days
Stock vesting period	4 years	4 years
Share-based compensation expense	$ 5.7	$ 4.4
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 32.1
Stock vesting period	3 years 1 month 6 days
Stock vesting period	4 years	4 years
Share-based compensation expense	$ 3.3
Restricted stock units granted	400,000	300,000
Performance-based RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 7.5
RSU with performance-based vesting requirements outstanding	400,000
Share-based compensation expense		$ 2.5
Restricted stock units granted		200,000
Performance-based RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period		4 years
Performance-based RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock vesting period		5 years

Weighted-Average Assumptions fo

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Detail) - Stock Options	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.00%	1.40%
Expected volatility of common stock	58.10%	60.00%
Dividend yield	0.00%	0.00%
Expected option term	5 years 9 months 18 days	5 years 7 months 6 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017shares
February Two Thousand Seventeen Shelf Registration [Member]
Class of Stock [Line Items]
Number of securities sold	0

Real Estate - Additional Inform

Real Estate - Additional Information (Detail) ft² in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2007USD ($)Building	Mar. 31, 2017USD ($)ft²RenewalOptionsLease_Agreements	Mar. 31, 2016USD ($)	Dec. 31, 2008USD ($)
Real Estate Properties [Line Items]
Sale of facility and associated real property	$ 109,000,000
Mortgage debt retired	47,700,000
Cash received net of transaction costs and debt retirement	$ 61,000,000
Leaseback transaction lease period	12 years
Number of building leased | Building	2
Net deferred gain on real estate sale		$ 10,000,000		$ 39,100,000
Deferred gain recognized on real estate sale		$ 900,000	$ 900,000
Lease expiration year		2,019
Percentage of management fee included in the base annual rent		3.50%
Letter of credit		$ 4,600,000
Lease extension period		10 years
Number of times to renew the lease contract | RenewalOptions		2
Subleased area | ft²		16
Rental income from sublease agreement		$ 600,000
Increase in deferred rent		$ (114,000)	(64,000)
Sublease
Real Estate Properties [Line Items]
Number of sublease agreements | Lease_Agreements		1
Lease renewal additional periods		1 year
Reversal of cease use expense		$ 800,000
Increase in deferred rent		$ 200,000	$ 246,000
Second Sublease
Real Estate Properties [Line Items]
Lease renewal additional periods		1 year
Lease expiration date		2018-03

Changes to Accrued Cease-Use Li

Changes to Accrued Cease-Use Liability (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Beginning balance		$ 853	$ 1,983
Change in estimate	[1]	0	(830)
Payments		(66)	(110)
Ending balance		$ 787	$ 1,043
[1]	Change in estimate was offset by an increase in deferred rent of approximately $246,000 during the first quarter of 2016.

Changes to Accrued Cease-Use 34

Changes to Accrued Cease-Use Liability (Parenthetical) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Lease Commitments And Contingencies [Line Items]
Increase in deferred rent	$ (114,000)	$ (64,000)
Sublease
Lease Commitments And Contingencies [Line Items]
Increase in deferred rent	$ 200,000	$ 246,000

Loss Per Common Share - Additio

Loss Per Common Share - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Net loss	$ (78,326)	$ (19,264)
Shares of common stock excluded from computation of diluted earnings per share outstanding	1.4	0.5

BIAL Agreement - Additional Inf

BIAL Agreement - Additional Information (Detail) - B I A L $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
License Agreement [Line Items]
License agreement date	Feb. 9, 2017
Up-front license fees	$ 30
Milestone payables	$ 115

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event - 2.25% Convertible Senior Notes due May 2024 $ / shares in Units, $ in Thousands	1 Months Ended
	May 31, 2017USD ($)d$ / shares
Subsequent Event [Line Items]
Convertible senior notes, issuance date	May 31, 2017
Convertible senior notes principal amount	$ 517,500
Convertible senior notes interest percentage	2.25%
Convertible notes, Issuance Cost	$ 15,300
Convertible senior notes	7 years
Convertible senior notes convertible in to shares	13.1711
Convertible senior notes Converted amount	$ 1,000
Convertible senior notes conversion price | $ / shares	$ 75.92
Threshold common stock trading days | d	20
Threshold consecutive common stock trading days	30 days
Threshold percentage of common stock price trigger	130.00%
Convertible senior notes convertible latest date	May 15, 2024
Convertible senior notes interest rate	2.25%
Convertible senior notes redemption rate	100.00%